Raffles Medical Group (RMG)

SINGAPORE (Jan 8): CIMB is maintaining its “add” call on Raffles Medical Group (RMG) with a target price of $1.24.

SINGAPORE (Jan 8): Although healthcare stocks in Singapore underperformed last year largely due to the setting up of new hospitals overseas, CIMB says the sector would be rerated once they stabilised.

SINGAPORE (Oct 31): Analysts are adjusting their forecasts and recommendations on Raffles Medical Group (RMG) after the management unveiled more information regarding its upcoming hospitals in China.

SINGAPORE (Sept 21): UOB Kay Hian is upgrading its call on Raffles Medical Group (RMG) to “buy” from “hold” with a target price of $1.28.

SINGAPORE (Sept 18): CIMB Research is upgrading its call on Raffles Medical Group (RMG) to “add” from “reduce” with a lower price target of $1.21 from $1.25 previously on the belief that the stock is looking attractive to gain exposure to the grow

SINGAPORE (July 31): Raffles Medical Group (RMG) has announced earnings of $16.8 million for the second quarter ended June, up half a percent from $16.7 million reported in the same period a year ago.

SINGAPORE (June 20): CIMB Research is keeping its “reduce” rating on Raffles Medical Group (RMG) and lowering its target price by 12 cents to $1.25.

SINGAPORE (June 5): Maybank Kim Eng Research continues to rate Raffles Medical Group (RMG) at “buy” as Singapore’s leading integrated healthcare provider, with a “robust track record and exciting development plans” of two hospitals in China.

SINGAPORE (April 25): RHB and Maybank Kim Eng Research have lowered their price targets on Raffles Medical Group (RMG) to $1.49 from $1.72, and to $1.67 from $1.70 respectively after the group posted a marginal 1.7% decline in 1Q17 revenue yesterday on so

SINGAPORE (Feb 20): Singapore Medical Group could see a re-rating as its market recognition and track record grows following its tie-up with Korean healthcare group CHA Medical Group, according to Maybank Kim Eng.